Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP19 | O94966 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28432857 | 0.98 | USP19 (0.40) | USP19CHRM5ADRA2COPRM1OPRK1 | |
| SCHEMBL28466818 | 0.98 | USP19 (0.42) | USP19CHRM5ADRA2COPRM1OPRK1 | |
| Bromide SCHEMBL28429216 | 0.97 | USP19 (0.42) | USP19CHRM5ADRA2COPRM1OPRK1 | |
| SCHEMBL1583393 | 0.96 | USP19 (0.38) | USP19CHRM5ADRA2COPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL1584061 | 0.95 | USP19 (0.38) | USP19CHRM5ADRA2COPRM1OPRK1 | |
| SCHEMBL1583511 | 0.93 | USP19 (0.35) | USP19DRD2P2RX7 | |
| Hydrochloric Acid SCHEMBL2650625 | 0.91 | USP19 (0.34) | USP19DRD2 | |
| SCHEMBL15000803 | 0.85 | KDM4E (0.33) | USP19DRD2 | |
| SCHEMBL10153613 | 0.81 | USP19 (0.41) | USP19PIM1 | |
| SCHEMBL25045245 | 0.81 | USP19 (0.31) | USP19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101892-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | USP19 4306/4885CHRM5 1057/4885ADRA2C 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.